2'-(2-chlorophenyl)-7'-methoxyspiro[1,3-oxazole-4,9'-xanthen]-2-amine | 1215864-55-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 2'-(2-chlorophenyl)-7'-methoxyspiro[1,3-oxazole-4,9'-xanthen]-2-amine
• 英文别名: 2'-(2-chlorophenyl)-7'-methoxyspiro[5H-1,3-oxazole-4,9'-xanthene]-2-amine
• CAS: 1215864-55-3
• 化学式: C₂₂H₁₇ClN₂O₃
• 分子量: 392.842
• InChiKey: CPTSXKPUIKUWDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  66.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2'-(2-chlorophenyl)-7'-methoxyspiro[1,3-oxazole-4,9'-xanthen]-2-amine 、 三氟乙酸 以 水 、 乙腈 为溶剂， 生成 2'-(2-chlorophenyl)-7'-methoxy-5H-spiro[oxazole-4,9'-xanthen]-2-amine 2,2,2-trifluoroacetate
  参考文献：
  名称：

  Structure- and Property-Based Design of Aminooxazoline Xanthenes as Selective, Orally Efficacious, and CNS Penetrable BACE Inhibitors for the Treatment of Alzheimer’s Disease

  摘要：

  A structure- and property-based drug design approach was employed to identify aminooxazoline xanthenes as potent and selective human beta-secretase inhibitors. These compounds exhibited good isolated enzyme, cell potency, and selectivity against the structurally related aspartyl protease cathepsin D. Our efforts resulted in the identification of a potent, orally bioavailable CNS penetrant compound that exhibited in vivo efficacy. A single oral dose of compound ha resulted in a significant reduction of CNS A beta 40 in naive rats.

  DOI：

  10.1021/jm300598e
• 作为产物：
  描述：

  2-溴-5-甲氧基苯甲酸 在 ammonium hydroxide 、 四(三苯基膦)钯 、 硫酸 、 碘 、 copper(II) bis(trifluoromethanesulfonate) 、 sodium carbonate 、 caesium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醚 、 乙酸乙酯 、 甲苯 、 正戊烷 为溶剂， 反应 85.92h， 生成 2'-(2-chlorophenyl)-7'-methoxyspiro[1,3-oxazole-4,9'-xanthen]-2-amine
  参考文献：
  名称：

  Structure- and Property-Based Design of Aminooxazoline Xanthenes as Selective, Orally Efficacious, and CNS Penetrable BACE Inhibitors for the Treatment of Alzheimer’s Disease

  摘要：

  A structure- and property-based drug design approach was employed to identify aminooxazoline xanthenes as potent and selective human beta-secretase inhibitors. These compounds exhibited good isolated enzyme, cell potency, and selectivity against the structurally related aspartyl protease cathepsin D. Our efforts resulted in the identification of a potent, orally bioavailable CNS penetrant compound that exhibited in vivo efficacy. A single oral dose of compound ha resulted in a significant reduction of CNS A beta 40 in naive rats.

  DOI：

  10.1021/jm300598e

文献信息

• [EN] SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE<br/>[FR] COMPOSÉS CYCLIQUES SPIRO-TÉTRACYCLIQUES UTILES EN TANT QUE MODULATEURS DE LA BÊTA-SÉCRÉTASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2010030954A1

  公开（公告）日：2010-03-18

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I); wherein A1, A2, A3, A4, A5, A6, T1, T2, W, X, Y and Z of Formula (I) are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula (I).

  本发明涉及一类新的化合物，用于调节β-分泌酶酶活性，并用于治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）及相关疾病。在一种实施例中，这些化合物具有一般的化学式（I）；其中化学式（I）中的A1、A2、A3、A4、A5、A6、T1、T2、W、X、Y和Z在此处定义。该发明还包括将这些化合物用于制备用于治疗与β-分泌酶蛋白活性相关的疾病和症状的药物组合物。这些疾病包括例如阿尔茨海默病、认知缺陷、认知障碍、精神分裂症以及与大脑斑块的形成和/或沉积相关和/或由此引起的其他中枢神经系统疾病。该发明还涵盖了化学式I的进一步实施例、中间体和用于制备化合物的有用过程。
• SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE
  申请人：White Ryan

  公开号：US20100087429A1

  公开（公告）日：2010-04-08

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , T 1 , T 2 , W, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

  本发明涉及一类新化合物，可用于调节Beta-分泌酶酶活性和治疗Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关病症。其中，一种实施方式是化合物具有通式I，其中通式I中的A1、A2、A3、A4、A5、A6、T1、T2、W、X、Y和Z的定义在此。本发明还包括这些化合物在制备用于治疗与beta-分泌酶蛋白活性相关的疾病和病症的药物组合物中的使用，包括阿尔茨海默病、认知障碍、认知损伤、精神分裂症和其他与大脑斑块的形成和/或沉积相关和/或由此引起的中枢神经系统病症。本发明还包括通式I的进一步实施方式、中间体和制备通式I化合物的有用过程。
• SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE
  申请人：Amgen Inc.

  公开号：EP2328903B1

  公开（公告）日：2014-03-05
• US8426447B2
  申请人：——

  公开号：US8426447B2

  公开（公告）日：2013-04-23
• Structure- and Property-Based Design of Aminooxazoline Xanthenes as Selective, Orally Efficacious, and CNS Penetrable BACE Inhibitors for the Treatment of Alzheimer’s Disease
  作者：Hongbing Huang、Daniel S. La、Alan C. Cheng、Douglas A. Whittington、Vinod F. Patel、Kui Chen、Thomas A. Dineen、Oleg Epstein、Russell Graceffa、Dean Hickman、Y.-H. Kiang、Steven Louie、Yi Luo、Robert C. Wahl、Paul H. Wen、Stephen Wood、Robert T. Fremeau

  DOI：10.1021/jm300598e

  日期：2012.11.8

  A structure- and property-based drug design approach was employed to identify aminooxazoline xanthenes as potent and selective human beta-secretase inhibitors. These compounds exhibited good isolated enzyme, cell potency, and selectivity against the structurally related aspartyl protease cathepsin D. Our efforts resulted in the identification of a potent, orally bioavailable CNS penetrant compound that exhibited in vivo efficacy. A single oral dose of compound ha resulted in a significant reduction of CNS A beta 40 in naive rats.